EMA has introduced email address authentication for EMA applications to improve security and usability of EMA applications by removing the need for users to remember their EMA username and password.  

Since 30 September 2024: 

  • All new self-registered users are automatically set by default to email authentication. 

  • All users not converted are requested to opt-in before 20 January 2025. 

Starting from 20 January 2025 the EMA will initiate the conversion of all users that didn’t opt-in to the email authentication:

  1. 20 January: Non regulatory users without specific application roles; 
  2. 3 February: Non regulatory users with application roles;
  3. 3 March: Regulatory users (European medicines regulatory network);
  4. 31 March: all users are converted. 

How to opt in: Users are required to opt-in to email authentication in EMA Account Management by following the enclosed detailed instructions. Once converted to email authentication, users can use email address to authenticate into EMA systems. 

Useful links: 

Contact: EMA Service Desk; If you are unable to access Service Desk, please send an email to servicenow@ema.europa.eu indicating your name, surname and your unique username.